The global market for Molecular Imaging was estimated at US$8.6 Billion in 2024 and is projected to reach US$10.4 Billion by 2030, growing at a CAGR of 3.3% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Molecular Imaging market.
Segments: Modality (Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality, Other Modalities); Application (Oncology Application, Cardiovascular Application, Neurology Application, Respiratory Application, Other Applications); End-Use (Hospitals End-Use, Diagnostic Imaging Centers End-Use, Research Institutes End-Use)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
Global Molecular Imaging Market - Key Trends & Drivers Summarized
How Is Molecular Imaging Revolutionizing Precision Medicine and Early Disease Detection?
Molecular imaging has emerged as a cornerstone technology in modern healthcare, offering unparalleled insights into biological processes at the molecular and cellular levels. Unlike traditional imaging modalities that primarily focus on anatomical structures, molecular imaging provides functional and metabolic information that aids in early disease detection, staging, and personalized treatment planning. The rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurodegenerative conditions has intensified the need for more precise diagnostic tools. Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), and hybrid imaging techniques such as PET-CT and PET-MRI have transformed diagnostic workflows by enabling real-time tracking of disease progression and treatment response. The growing integration of radiopharmaceuticals, which serve as biomarkers for targeted imaging, is further enhancing diagnostic accuracy and patient outcomes. As the demand for non-invasive and early detection methods rises, molecular imaging continues to gain widespread adoption across hospitals, research institutions, and pharmaceutical industries, reinforcing its pivotal role in precision medicine.What Technological Advancements Are Driving the Molecular Imaging Market?
The molecular imaging market is witnessing a rapid transformation, driven by continuous advancements in imaging modalities, artificial intelligence (AI), and radiopharmaceuticals. AI-powered imaging analytics have enabled faster and more precise interpretation of complex imaging data, reducing diagnostic errors and improving clinical decision-making. Additionally, the development of novel radiotracers targeting specific biomarkers has significantly enhanced the sensitivity and specificity of molecular imaging techniques. Hybrid imaging systems, such as PET-CT and SPECT-CT, have further refined the diagnostic landscape by providing integrated functional and anatomical insights in a single scan, thereby improving efficiency and patient comfort. The rise of optical and fluorescence-based molecular imaging is expanding applications in oncology and neurology, enabling researchers to visualize molecular activity in real-time. Moreover, miniaturized and portable molecular imaging devices are being developed to facilitate point-of-care diagnostics, particularly in resource-limited settings. As technology continues to evolve, the convergence of AI, machine learning, and next-generation imaging agents is expected to redefine the molecular imaging market, unlocking new possibilities for disease management and treatment optimization.How Is Regulatory and Market Dynamics Influencing Molecular Imaging Adoption?
Regulatory frameworks and market dynamics play a crucial role in shaping the growth of the molecular imaging sector. Stringent guidelines governing the approval and distribution of radiopharmaceuticals and imaging devices necessitate continuous innovation to meet safety and efficacy standards. Agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have imposed rigorous compliance measures to ensure the reliability and ethical use of molecular imaging technologies. At the same time, increasing investments from governments, healthcare institutions, and private entities are driving research and development initiatives in this space. The growing trend of public-private partnerships is facilitating the expansion of molecular imaging infrastructure in emerging economies, broadening access to advanced diagnostic services. Additionally, reimbursement policies for imaging procedures significantly impact market adoption, with favorable reimbursement models encouraging wider clinical utilization. Furthermore, the pharmaceutical industry`s reliance on molecular imaging for drug development and clinical trials is reinforcing the sector’s market potential. As regulatory landscapes continue to evolve, aligning innovation with compliance will be essential in sustaining market growth and expanding the accessibility of molecular imaging solutions.What Are the Key Factors Fueling the Growth of the Molecular Imaging Market?
The growth in the global molecular imaging market is driven by several factors, including rising disease burden, technological advancements, regulatory support, and increasing research investments. The growing incidence of cancer, cardiovascular diseases, and neurological disorders has amplified the need for early and accurate diagnosis, positioning molecular imaging as a critical tool in modern healthcare. Innovations in radiopharmaceuticals, AI-driven imaging analytics, and hybrid imaging systems have significantly enhanced diagnostic precision, leading to wider adoption across medical and research applications. The expansion of personalized medicine and targeted therapy approaches is also boosting demand for molecular imaging, as it enables tailored treatment strategies based on individual patient profiles. Additionally, increasing healthcare expenditures in emerging economies and the expansion of imaging infrastructure are driving market penetration in underserved regions. The pharmaceutical and biotechnology industries` dependence on molecular imaging for drug discovery, biomarker validation, and clinical trial monitoring is another key growth accelerator. Moreover, ongoing research into non-invasive imaging techniques and next-generation tracers is expected to expand the scope of molecular imaging applications. As healthcare systems worldwide prioritize early disease detection and precision medicine, the molecular imaging market is poised for sustained expansion, offering new opportunities for industry stakeholders and researchers alike.Report Scope
The report analyzes the Molecular Imaging market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments: Modality (Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality, Other Modalities); Application (Oncology Application, Cardiovascular Application, Neurology Application, Respiratory Application, Other Applications); End-Use (Hospitals End-Use, Diagnostic Imaging Centers End-Use, Research Institutes End-Use)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Single Photon Emission Computed Tomography Modality segment, which is expected to reach US$4.6 Billion by 2030 with a CAGR of a 3.3%. The Positron Emission Tomography Modality segment is also set to grow at 4.1% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $2.3 Billion in 2024, and China, forecasted to grow at an impressive 6.1% CAGR to reach $2.1 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Molecular Imaging Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Molecular Imaging Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Molecular Imaging Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Abbott Laboratories, Bio-Rad Laboratories, Bruker Corporation, Canon Medical Systems Corporation, Cubresa Inc. and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 47 Featured):
- Abbott Laboratories
- Bio-Rad Laboratories
- Bruker Corporation
- Canon Medical Systems Corporation
- Cubresa Inc.
- Esaote
- GE HealthCare
- Koninklijke Philips N.V.
- Mediso
- PerkinElmer
- PerkinElmer Inc.
- Positron Corporation
- QIAGEN
- Roche Diagnostics
- Shimadzu Corporation
- Siemens AG
- Siemens Healthineers
- Thermo Fisher Scientific
- United Imaging Healthcare Co.
Tariff Impact Analysis: Key Insights for 2025
Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
What’s Included in This Edition:
- Tariff-adjusted market forecasts by region and segment
- Analysis of cost and supply chain implications by sourcing and trade exposure
- Strategic insights into geographic shifts
Buyers receive a free July 2025 update with:
- Finalized tariff impacts and new trade agreement effects
- Updated projections reflecting global sourcing and cost shifts
- Expanded country-specific coverage across the industry
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Bio-Rad Laboratories
- Bruker Corporation
- Canon Medical Systems Corporation
- Cubresa Inc.
- Esaote
- GE HealthCare
- Koninklijke Philips N.V.
- Mediso
- PerkinElmer
- PerkinElmer Inc.
- Positron Corporation
- QIAGEN
- Roche Diagnostics
- Shimadzu Corporation
- Siemens AG
- Siemens Healthineers
- Thermo Fisher Scientific
- United Imaging Healthcare Co.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 392 |
Published | April 2025 |
Forecast Period | 2024 - 2030 |
Estimated Market Value ( USD | $ 8.6 Billion |
Forecasted Market Value ( USD | $ 10.4 Billion |
Compound Annual Growth Rate | 3.3% |
Regions Covered | Global |